Insmed Q3 Revenue Hits $524.4M as BRINSUPRI Grows 29% Sequentially, Guidance Raised
INSM is trading near its 52-week low of $90.39 (9.3% above the low).
Summary
Insmed posted Q3 2026 total revenue of $524.4 million, up 268% from $142.3 million a year ago, with BRINSUPRI contributing $400.1 million — 29% growth over Q2's launch-driven base. ARIKAYCE added $124.4 million, up 9% year-over-year on international strength. The company raised the low end of full-year BRINSUPRI guidance to $1.35-1.4 billion (from $1.25-1.4 billion) and ARIKAYCE to $460-470 million (from $450-470 million). Net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million a year earlier, though R&D ($270.0 million) and SG&A ($253.0 million) both climbed on TPIP development and BRINSUPRI commercialization spend. This follows the Q2 blowout that sent shares up 33% in August; the sequential BRINSUPRI growth and guidance raise confirm the launch curve is holding. The FDA's Priority Review of the ARIKAYCE sNDA carries a PDUFA target of January 28, 2027, and Japan PMDA submission of ENCORE data is planned for Q4 2026.
At the time of this announcement, INSM was trading at $98.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.